Is it hayfever or just another cold? How to tell the difference in kids

The question every parent asks

It starts around week three. Another box of tissues, another week of sniffling, another apologetic note to the school. You've already ruled out a second cold — or have you? The frustrating truth is that distinguishing hayfever from a virus in a child is genuinely difficult, even for experienced clinicians. And getting it right matters more in children than most parents realise — because childhood hayfever isn't just an inconvenience. Left unrecognised, it quietly chips away at concentration, sleep, and the school years that shape everything that follows.

This article pulls together the best available evidence on how hayfever presents differently in children, what treatments are safe at various life stages (including pregnancy), and where the science is honest about its own limits.

---

The science: how childhood hayfever is different

Hayfever in children and adults share the same underlying biology — an immune system that has mistaken pollen (or dust mite, or mould) for a threat, triggering an IgE-mediated response that floods nasal tissue with histamine, eosinophils, and inflammation. But from that shared starting point, the two experiences diverge considerably.

Izquierdo-Domínguez et al. (2017), drawing on the Spanish ADRIAL cohort, found that children more often experience intermittent, seasonal disease — classic spring and summer hayfever — while adults tend toward persistent, year-round symptoms. Paradoxically, children's symptoms are often classified as more severe on clinical measures, even though children themselves tend to report less subjective distress than adults do. This isn't stoicism — it's a developmental difference in how symptoms are perceived and communicated.

The more clinically significant difference is what hayfever travels with in children. The paediatric immune system is in an active sensitisation phase, prone to what immunologists call the atopic march: a sequential progression, in susceptible children, from eczema in infancy to allergic rhinitis in toddlerhood to asthma in the school years (Swain, 2025). This progression is driven by a Th2-skewed immune response — the arm of the immune system that handles parasites and, in people with atopy, overreacts to harmless environmental triggers.

Beyond the atopic march, children face anatomical complications that adults simply don't. Immature Eustachian tubes and enlarged adenoidal tissue mean that nasal obstruction in a child with hayfever carries real risk of middle ear fluid, hearing difficulties, and sinus problems (Izquierdo-Domínguez et al., 2013). These aren't rare edge cases — they're common enough to warrant attention at every hayfever review.

The quality-of-life burden also looks different. Adults lose sleep and workdays. Children lose concentration, fall behind in class, and miss the developmental windows that matter. A child who can't breathe through their nose, can't sleep properly, and can't focus in the classroom isn't just uncomfortable — they're disadvantaged in ways that compound.

---

Is it hayfever or a cold? What the evidence can — and can't — tell you

This is the question parents most want answered, and the honest answer is: no single sign reliably settles it.

Fever is the most useful pointer. Allergic rhinitis is a localised mucosal process — histamine, IL-4, IL-5, and IL-13 don't meaningfully activate the hypothalamic thermostat. Fever in confirmed allergic rhinitis is rare, occurring in fewer than 5% of cases. So if your child has a temperature, a viral or bacterial infection is the much more likely explanation. But the reverse doesn't hold: afebrile colds are common, especially after the first couple of days, so the absence of fever doesn't confirm hayfever (synthesised from Doan et al., 2014; Buonsenso et al., 2024).

Duration provides a softer signal. Common colds are self-limited — the host's antiviral immune response typically clears the virus within 7–14 days. Allergic rhinitis, driven by ongoing allergen exposure rather than a replicating pathogen, persists as long as the trigger is present. The ARIA classification of persistent allergic rhinitis requires symptoms on more than four days per week for more than four consecutive weeks — a useful benchmark, though it was designed to classify AR phenotype rather than rule out colds at first presentation. Clinically, symptoms lasting beyond 14–21 days without improvement shift the probability meaningfully toward allergy (Goniotakis et al., 2023; Topal et al., 2014).

Symptom quality matters too. Intense nasal itch, paroxysmal sneezing, watery (rather than thick or coloured) discharge, and eye symptoms — itchy, red, watery eyes — are more characteristic of allergy. Systemic symptoms like muscle aches, sore throat, or general malaise point toward infection. But there's enough overlap that no symptom constellation alone is diagnostic.

As for a quick parent-completed checklist: despite the obvious appeal, none has been formally validated for distinguishing allergic rhinitis from acute viral URI in children at the point of presentation. ISAAC-derived questionnaires — designed for epidemiological surveillance — achieve around 70–80% sensitivity and 70–85% specificity for identifying atopic children, but they weren't built as real-time triage tools, and their comparator is atopy broadly, not an acute cold (Kim et al., 2012; Taylor et al., 2010).

The practical upshot: if your child's symptoms are seasonal, triggered by outdoors exposure, accompanied by itchy eyes, and have lasted more than two weeks without improvement — and particularly if there's a personal or family history of eczema or asthma — hayfever becomes the working diagnosis worth investigating.

---

Treatment that's safe and effective in children

The good news: the evidence base for treating childhood hayfever is solid, and the options are well-tolerated.

Second-generation antihistamines — cetirizine, loratadine, and fexofenadine — are first-line for mild-to-moderate symptoms. They selectively block peripheral H1 receptors with minimal crossing into the brain, meaning they relieve itch, sneezing, and runny nose without significant sedation. These are well-studied in children and have reassuring long-term safety records (Phan et al., 2012).

Intranasal corticosteroids (mometasone, fluticasone, triamcinolone) are the most effective treatment for moderate-to-severe or persistent symptoms, particularly nasal congestion — which antihistamines alone handle poorly. They work by suppressing local eosinophilic inflammation and reducing vascular permeability in the nasal lining. Because they act locally with minimal systemic absorption at licensed doses, concerns about growth suppression — a question that comes up with any steroid in children — are not supported by evidence at standard intranasal doses (Phan et al., 2012; Vidal & Cortez, 2025).

Combined intranasal therapy — a single spray delivering both an antihistamine and a corticosteroid (such as azelastine plus fluticasone) — is emerging as an option, including in younger children. Early evidence is encouraging, but the paediatric data are limited to a small number of studies, and large randomised trials in children under 12 are still lacking (Berger et al., 2020; Vidal & Cortez, 2025).

Sublingual immunotherapy (allergy drops taken under the tongue) is the only treatment that addresses the underlying sensitisation rather than just the symptoms. Systematic reviews suggest it is effective for allergic rhinitis in children, with a good safety profile — though protocols vary and it requires sustained commitment over two to three years (Garcia Jaramillo et al., 2024).

---

A note for pregnancy: what's safe when hayfever peaks

Hayfever during pregnancy is common, and undertreating it — because of understandable anxiety about medication — can affect sleep, wellbeing, and quality of life at an already demanding time. The evidence here is reassuring, though not perfect.

Intranasal corticosteroids (budesonide, fluticasone, mometasone) are generally considered the safest pharmacological option. Nasal delivery means systemic absorption is minimal, so fetal exposure is very low. Budesonide has the longest safety track record in pregnancy and is often cited as the preferred intranasal corticosteroid by international guidelines (Gilbert et al., 2005).

Second-generation antihistamines — loratadine and cetirizine — have reassuring safety data from large registry studies involving hundreds of thousands of pregnancies, with no consistent signal for congenital malformations (Mazzotta et al., 1999; Gilbert et al., 2005). Loratadine has slightly more data specifically in pregnancy; cetirizine's record is also strong.

Oral decongestants (pseudoephedrine, phenylephrine) should be avoided in the first trimester. There is an association between first-trimester pseudoephedrine use and gastroschisis — a serious abdominal wall defect — and while the absolute risk remains low, the risk-benefit calculation doesn't support routine use in early pregnancy (Loock, 2009; Sato, 2012).

The evidence base here relies on observational registry data rather than randomised trials — ethically impossible to conduct in pregnant women — so confidence is moderate rather than high. Always discuss medication choices with your GP or midwife, particularly if you're in the first trimester or have any complicating factors.

---

What about breastfeeding and allergy prevention?

Breast milk contains secretory IgA, immunomodulatory factors, and pre-digested allergens bound to maternal antibodies — the biological ingredients for educating an infant's immune system toward tolerance rather than sensitisation. It also shapes the early gut microbiome in ways that support immune regulatory pathways.

Multiple systematic reviews and meta-analyses support a modest protective association between longer breastfeeding duration and reduced allergic rhinitis risk in children under five, and reduced asthma risk in older children (Hoang et al., 2021; Alotiby, 2023). The effect is more consistent in low- and middle-income countries, where formula feeding is associated with greater infectious and nutritional risk, making the comparison less clean in high-income settings.

The honest caveat: the evidence is conflicting across different allergy types, the studies are observational (impossible to randomise), heterogeneity between trials is high, and whether any protective effect persists meaningfully into later childhood remains unclear (Matheson et al., 2012). Breastfeeding has substantial independent benefits — immunity, nutrition, bonding — but choosing to breastfeed specifically to prevent hayfever is not something the current evidence strongly supports as a certainty.

---

The evidence landscape: what we know confidently, and what we don't

The differences between adult and childhood hayfever are well-characterised, with moderate-confidence evidence from observational cohorts including ADRIAL. Treatment evidence — antihistamines, intranasal corticosteroids — is solid and underpins international guidelines. Pregnancy safety data are reassuring but observational.

Where the evidence is genuinely thin: no validated parent-completed checklist exists for distinguishing a cold from hayfever in real-time. No formal diagnostic accuracy study has validated fever absence or symptom duration as standalone discriminators in children aged 3–12 with dual reference standards (viral PCR plus allergy testing). The local allergic rhinitis phenotype — where children have all the symptoms of hayfever but test negative on standard skin-prick and blood tests — remains substantially undercharacterised in paediatric populations (Matsumoto et al., 2022).

---

What Haelo recommends

For parents trying to tell hayfever from a cold:

• Note whether symptoms are seasonal and linked to outdoor exposure, and whether they affect the eyes as well as the nose.
• A temperature strongly suggests infection. No temperature after day three or four, with ongoing sneezing, itch, and watery eyes, shifts the odds toward allergy.
• Symptoms persisting beyond 14 days without improvement are worth discussing with your GP as possible allergic rhinitis.
• A family or personal history of eczema, asthma, or existing allergies meaningfully raises the prior probability.

For treating hayfever in children:

• Start with a second-generation antihistamine (cetirizine or loratadine) for mild symptoms — take it in the morning on high-pollen days.
• If congestion is the dominant problem or symptoms are moderate-to-severe, an intranasal corticosteroid is more effective. Use it consistently — it takes a few days to reach full effect.
• If symptoms are significantly affecting school performance or sleep, ask your GP about allergy testing and whether immunotherapy is appropriate.

If you're pregnant:

• Loratadine or cetirizine are reasonable first choices for antihistamines — discuss with your GP.
• Intranasal budesonide or fluticasone are the preferred corticosteroid options.
• Avoid oral decongestants in the first trimester.

On breastfeeding:

• Breastfeed because it is good for your baby in many documented ways. If allergy prevention is one hoped-for benefit, the evidence is plausible but not yet robust enough to treat it as guaranteed.